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Abstract
Background: Despite omega-3 polyunsaturated fatty acids (PUFA) supplementation in depressed patients have been
suggested to improve depressive symptomatology, previous findings are not univocal.
Objectives: To conduct an updated meta-analysis of randomized controlled trials (RCTs) of omega-3 PUFA treatment of
depressive disorders, taking into account the clinical differences among patients included in the studies.
Methods: A search on MEDLINE, EMBASE, PsycInfo, and the Cochrane Database of RCTs using omega-3 PUFA on patients
with depressive symptoms published up to August 2013 was performed. Standardized mean difference in clinical measure
of depression severity was primary outcome. Type of omega-3 used (particularly eicosapentaenoic acid [EPA] and
docosahexaenoic acid [DHA]) and omega-3 as mono- or adjuvant therapy was also examined. Meta-regression analyses
assessed the effects of study size, baseline depression severity, trial duration, dose of omega-3, and age of patients.
Results: Meta-analysis of 11 and 8 trials conducted respectively on patients with a DSM-defined diagnosis of major
depressive disorder (MDD) and patients with depressive symptomatology but no diagnosis of MDD demonstrated
significant clinical benefit of omega-3 PUFA treatment compared to placebo (standardized difference in random-effects
model 0.56 SD [95% CI: 0.20, 0.92] and 0.22 SD [95% CI: 0.01, 0.43], respectively; pooled analysis was 0.38 SD [95% CI: 0.18,
0.59]). Use of mainly EPA within the preparation, rather than DHA, influenced final clinical efficacy. Significant clinical efficacy
had the use of omega-3 PUFA as adjuvant rather than mono-therapy. No relation between efficacy and study size, baseline
depression severity, trial duration, age of patients, and study quality was found. Omega-3 PUFA resulted effective in RCTs on
patients with bipolar disorder, whereas no evidence was found for those exploring their efficacy on depressive symptoms in
young populations, perinatal depression, primary disease other than depression and healthy subjects.
Conclusions: The use of omega-3 PUFA is effective in patients with diagnosis of MDD and on depressive patients without
diagnosis of MDD.
Citation: Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, et al. (2014) Role of Omega-3 Fatty Acids in the Treatment of Depressive Disorders: A
Comprehensive Meta-Analysis of Randomized Clinical Trials. PLoS ONE 9(5): e96905. doi:10.1371/journal.pone.0096905
Editor: German Malaga, Universidad Peruana Cayetano Heredia, Peru
Received December 3, 2013; Accepted April 11, 2014; Published May 7, 2014
Copyright:  2014 Grosso et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Giuseppe Grosso and Sabrina Castellano were supported by the International Ph.D. Program in Neuropharmacology, University of Catania, Catania,
Italy. The contributors had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: giuseppe.grosso@studium.unict.it
Introduction
Omega-3 polyunsaturated fatty acids (PUFA) eicosapentaeoic
acid (EPA) and docosahexaenoic acid (DHA) have been demon-
strated to be effective in cardiovascular disease (CVD) prevention
due to their anti-inflammatory and cardio-protective effects [1].
Recently, new therapeutic indications for omega-3 PUFA have
been proposed, such as treatment for certain forms of mental
illness, including depressive disorders [2]. Indeed, some psychiatric
diseases as depression may share certain pathophysiological
mechanisms with CVD, namely increased production of
pro-inflammatory cytokines, endothelial dysfunction, and eleva-
tions in plasma homocysteine levels [3–5]. The positive effects of
omega-3 PUFA on depression may depend on their physiological
abundant content in the human nervous system and their
involvement in neurogenesis and neuroplasticity [6]. Moreover,
their anti-inflammatory capacity may counteract inflammatory
processes occurring in depression [7,8]. Several ecological, cross-
sectional, and prospective studies supported such hypotheses by
reporting an inverse association between omega-3 intake and
prevalence of depression [2]. Further clinical studies demonstrated
lower concentration of omega-3 PUFA in plasma or red blood cell
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membranes of depressed subjects [9–13]. All together, these
observations suggest a correlation between omega-3 PUFA and
depressive disorders, justifing the rationale of a number of
randomized controlled trials (RCTs) of omega-3 PUFA supple-
mentation for the treatment of depressive disorders. The overall
analysis of these studies from previous meta-analyses suggested a
general benefit of omega-3 PUFA on depressive symptoms, despite
certain variability in results weakened the possible validity of the
findings. Indeed, results of such studies are not univocal,
jeopardizing the evidence of therapeutic implications of omega-3
PUFA in depressed patients. It has been suggested that the
heterogeneity between studies may depend on clinical and
methodological issues, such as severity of baseline depression
and methods of assessment and diagnosis of depression. Some
important issues regarding therapeutic regimen have been
explored in more recent meta-analysis, reporting that the positive
effects of omega-3 PUFA on depressive symptoms appeared to
depend more on EPA administration rather than DHA, severity of
depression, and study quality [14]. However, some concerns
regarding these findings still persist [15,16]. The analyses
previously conducted focused on the effects of omega-3 PUFA
supplementation on depressive symptoms, but features associated
with the pathophysiological nature of the depression occurring in
the patients and their comorbidity status were often lacking. It is
reasonable to believe that the biological effects of omega-3 PUFA
may result effective in certain subtypes of depressive disorders
rather than in others due to the different type of depression or
clinical phenotype of the patient. Despite a full understanding of
the processes leading to the depressive status is lacking, primary
psychiatric disorders, such as major depression disorder (MDD)
and bipolar disorders, are specific psychiatric conditions as
recognized in the American Psychiatric Association’s revised
fourth edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) [17], marking out specific depressive
symptoms that should be present as inclusion criteria to determine
MDD diagnosis. The mental health examination may include the
use of rating scales, such as the Hamilton Rating Scale for
Depression [18], the Beck Depression Inventory [19], or the
MARDS [20] for MDD, and the bipolar spectrum diagnostic scale
[21] for bipolar disorders. These psychiatric diseases have indeed
specific biological causes and are often known to be treated with
and respond to different pharmacological interventions [22].
Another specific pathological condition is perinatal depression,
which indicates the occurrence of depressive and other mood-
associated symptoms during pregnancy and lactation, with a range
of 5–25% of women developing post-partum depression [23].
Pregnancy and lactation are challenging periods due to a higher
demand of omega-3 PUFA from the fetus and the newborn,
respectively, and a low DHA status may induce depressive
symptoms [24]. Despite the fact that it is not clear if the depressive
status is caused by or simply precipitated by pregnancy and
lactation conditions, it is however likely associated with these
conditions rather than with the aforementioned causes of MDD.
Similarly, psychiatric disorders occurring in young populations
need special attentions because major differences between adult
and juvenile depression have been well-documented, despite the
reasons for such dissimilarities are not clear [25]. Actually, there is
very limited evidence upon which to base conclusions about the
relative effectiveness of psychological interventions or antidepres-
sant medication, but effectiveness of these interventions cannot be
fully established [26]. Finally, the occurrence of depression
secondary to a different primary disease, for instance schizophre-
nia, Alzheimer’s disease (AD), Parkinson’s disease, and CVD, may
raise doubts on the pathophysiological mechanisms that cause the
depressive symptomatology. In addition, despite it is of interested
to examine the role of omega-3 PUFA on potential mood
depression in healthy subjects, it is important to underline that
preventive and therapeutic pathways may differ each other. Thus,
altogether, the choice in previous meta-analyses to pool together
studies with such different baseline conditions, in which depression
occurred, may have affected the quality of the studies as well as
utilizability of the results [27,28]. Moreover, the last meta-analysis
included studies up to 2010 [29]. Thus, the aim of this study was to
update the current knowledge about the overall clinical efficacy of
omega-3 fatty acids (particularly EPA and DHA) in previous and
more recent RCTs published in the last years, minimizing, from a
clinical point of view, the differences among the populations of
patients included in the studies, finally focusing on patients with a
DSM-defined diagnosis of MDD.
Methods
A comprehensive search on MEDLINE, EMBASE, PsycInfo,
and the Cochrane Database systematic Reviews of all RCTs using
omega-3 PUFA on patients with depressive symptoms published
up to August 2013 was performed. Articles of potential interest
were identified by using the following search terms: ‘‘omega-3’’,
‘‘polyunsaturated fatty acids’’, ‘‘PUFA’’, ‘‘trial’’, ‘‘EPA’’, ‘‘DHA’’,
combined with the following terms: ‘‘depression’’, ‘‘depressive
disorder’’, ‘‘depressed mood’’, ‘‘bipolar’’, combined with ‘‘perina-
tal’’, ‘‘post-partum’’, ‘‘CVD’’, ‘‘schizophrenia’’, ‘‘Parkinson’’,
‘‘Alzheimer’’, ‘‘diabetes’’, ‘‘angina’’. Among the 192 articles
retrieved, RCTs were identified and screened by reading the
abstract and, when necessary, the full text, in order to select those
articles relevant for the analysis. The reference list of the relevant
reports was also inspected to identify any additional trials not
previously identified. The process of identification and inclusion of
trials is summarized in Figure 1. Inclusion criteria were the
following: (i) studies conducted on humans; (ii) randomized design;
(iii) placebo controlled; (iv) use of omega-3 PUFA supplement
which relative amount could be quantified; (v) exploring changes
in depressive symptoms as primary or secondary outcome.
Exclusion criteria were the following: (i) studies reporting
insufficient statistics or results; (ii) adopted a dietary intervention
design. Study quality was measured in a 13-point scale including
the Jadad criteria [30] and specific information regarding (i)
registration of RCT before conducting the study, (ii) adequate
blinding of the researchers, (iii) the use of an intention-to-treat
analysis, (iv) control for patients’ diet (i.e., number of servings of
fish), (v) assessment of compliance through measurement of plasma
fatty acids, (vi) significant differences at baseline, (vii) adequate
sample calculation, whether (viii) depression was the primary
outcome, and (ix) number and reasons of withdrawal were
mentioned. Data were abstracted independently from each
identified trial by GG and SM using a standard data abstraction
form. This process was independently performed by two
researchers and discordances were discussed and risolved.
Out of 59 originally selected studies, one [31] was excluded
because of having a non-randomize non-placebo controlled
design; two [32,33], because there was used a dietary intervention
design; five [34–38], because the depressive status was reported as
a categorical variable rather than a rating scale; two [39,40],
because an inadequate or poorly comparable rating score of
depression was used; two [41,42], because poorly comparable
omega-3 PUFA or placebo preparations. This selection strategy
resulted in a final selection of 47 studies eligible to be included in
the present systematic review.
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The clinical outcome of interest was the standardized mean
difference in the change from baseline to endpoint scores on a
depression rating scale, in patients taking omega-3 PUFA
supplements vs. patients taking placebo. Preferred rating scales
for measuring depression severity were the Hamilton Depression
Rating Scale (HDRS), either the 9-item short form, 17-item, 21-
item or 25-items scales, and the Montgomery Asberg Depression
Rating Scale (MADRS) [20,43,44]. When available, HDRS scores
from each study were used. If the HDRS was not available we
used the MADRS. If neither HDRS nor MADRS data were
available, we used the clinician rated measure of depression that
the investigators identified as their primary outcome.
Among selected RCTs lacking in data, such as means and/or
standard deviations (SDs), the data of one study [45] were
provided by authors; SDs and 95% confidence intervals (CIs) of
five studies [46–50] were retrieved from graphs; data of one study
[51] were medians; and data of three studies [52–54] were
imputed from data from all other trials using the same measure for
depression as described elsewhere [55]. Eight studies [56–63] were
finally excluded from the meta-analysis due to lacking data,
resulting in a total number of 39 studies to be included in the
analysis.
Effects due to participant diagnosis were investigated by
grouping studies according to the most relevant clinical charac-
teristics of the population on which they were conducted, as
follows: (i) Depressed patients (including DSM-defined diagnosis of
MDD and general assessment of depression without clinical visit);
(ii) Bipolar disorder patients (including bipolar disorder during
pregnancy); (iii) Children or adolescents with depression or bipolar
disorder; (iv) Women with perinatal depression (including DSM-
defined diagnosis of MDD and prevention of post-partum
depression); (v) Mild-cognitive impairment or AD patients; (vi)
Schizophrenic patients; (vii) Parkinson’s disease patients; (viii)
Patients with concomitant CVDs; and (ix) Healthy subjects.
Data regarding type of diagnosis, number of subjects enrolled in
the trial, on-going therapy, (TRATT.) type of supplement used in
the intervention, type of placebo, daily dose, duration of the
intervention, outcome measures, and information to retrieve the
study quality were collected. Those RCTs reporting more than
one dose of omega-3 PUFA [54,64–68] or more than one
formulation (i.e., EPA or DHA separately) [48,51,69], were
considered as separate studies in the pooled analyses. One study
[70] enrolled different populations (MDD and non-MDD
patients), thus each population was also included in the meta-
analysis as a separate study.
Statistical Analysis
Continuous data were reported as mean and SDs and listed in
descriptive tables. All depression scales’ means and SDs at baseline
and end of follow-up period of both intervention and control
groups were combined [71] and the standardized mean effect for
all trials was calculated by using Hedges adjusted g in order to
correct for small sample bias [72]. Both random- and fixed-effects
models were used to estimate the overall effect size. Heterogeneity
Figure 1. Process of inclusion of trials for systematic review and meta-analysis of studies on omega-3 fatty acids and depressive
symptoms.
doi:10.1371/journal.pone.0096905.g001
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was investigated by using Higgins’ I2 statistic [73,74]. When
heterogeneity between results of the studies exists, the random-
effect models were preferred.
Possible publication bias for the analysis regarding RCTs
conducted on MDD patients (MDD group, n = 11) and those not
diagnosed with DSM-IV criteria (non-MDD group, n = 9) was
investigated by drawing a funnel plot to look for funnel plot
asymmetry [71] and meta-regression based on study size. Meta-
regression was performed using linear regression, with the effect
size (SMD) of trials as the dependent variable and the variables of
interest as the independent variable. The generic inverse variance
method was used to weight trials. Effects due to severity of
depressive symptoms, age of patients, and study quality were also
investigated by using meta-regression based on standardized
baseline depression scores, mean age of the study participants,
and our modified Jadad scores of the studies, respectively. The
effects of trial duration, EPA and DHA dose in omega-3
preparations, and the use as mono or adjuvant therapy were also
examined. Particularly, the qualitative analysis of the type of
supplementation used was investigated grouping the studies in
those using mainly EPA (EPA .50% of the dose) and mainly
DHA (DHA .50% of the dose). A further analysis was computed
by splitting the grouping in mainly EPA, pure EPA, mainly DHA,
and pure DHA supplementation. As well, the therapeutic
approach was investigated by grouping studies using omega-3 in
monotherapy or as adjuvant therapy together with antidepressant
drugs. The quantitative analysis of the dose was computed by a
meta-regression analysis of the EPA and DHA doses used.
Random- and fixed-effects models, forest and funnel plots, and
Higgins’ I2 statistics were performed in Review Manager (Rev-
Man) version 5.2 (Copenhagen: The Nordic Cochrane Centre,
The Cochrane Collaboration), meta-regression analyses were
performed in SPSS version 17 (SPSS Inc., Chicago, IL, USA).
Results
Overall Studies
The most relevant features of the 47 studies included in this
systematic review and meta-analysis are displayed in Table 1.
Considerable differences among studies were found for all
characteristics examined. The average quality of the studies was
about 9 over a maximum score of 13 (range 5–13). The mean
length of the trials was about 16 weeks (range 4–160), 36 studies
used a mixed intervention with EPA+DHA, 14 pure EPA and 4
pure DHA. The average dose of EPA+DHA was 1.39 g (range
0.63–6.2 of EPA and 0.27–3.4 of DHA), whereas 1.93 g (range
Figure 2. Forest plot showing individual and combined effect size estimates and 95% CIs for 19 trials grouped in those conducted
on patients with a DSM-defined diagnosis of major depressive disorder (MDD group, n = 11) and those on patients with an
assessment of depression but not rigorously diagnosed according to the DSM criteria (non-MDD group, n = 8). Black squares: indicate
the weighting given to the trial in the overall pooled estimate; lines: indicate the 95% CIs; rhombus: indicate the combined effect size.
doi:10.1371/journal.pone.0096905.g002
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1–6) and 0.86 g (range 0.22–2) were the average doses of pure
EPA and DHA, respectively (Table 1). The most of RCTs used the
Hamilton Depression Rating Scale [46,48,49,54,57,58,63,65,69,75–
84], 10 studies [46,49,56,68,79,85–89] used the Beck Depression
Inventory, and 13 studies [47,50,54,62,64,67,77,84,90–94] the Mon-
tgomery-Asberg Depression Scale as the main outcome measure.
Among the studies not included in the quantitative analysis,due
to lack of data, one was conducted on patients with obsessive-
compulsive disorder [57] and one on patients with chronic
fatigue syndrome [56], both reporting no relevant effects of
omega-3 fatty acids compared with placebo; four studies
conducted in bipolar depressed patients [58,59,61,63] reporting
that there were no significant differences on any outcome
measure between the EPA and placebo groups; one study on
diabetes mellitus patients with MDD [62] reporting no effect of
omega-3 fatty acids on depression severity; and one on older
adults with mild cognitive impairment suggesting that increased
intakes of DHA and EPA can reduce depressive symptoms and
the risk of progressing to dementia [60].
Depression (MDD and Non-MDD Groups)
A total of 19 studies were included in the first pooled analysis
conducted in patients with depressive symptoms (Figure 2). Among
them, 11 trials were conducted in patients with a DSM-defined
diagnosis of MDD, including 8 studies conducted in adults
[46,48,70,76–78,83,84] and 3 studies in elderly patients
[53,95,96]. The pooled standardized difference in means using a
fixed-effects model for the MDD group was 0.47 SD (95% CI:
0.29, 0.66), which suggests a beneficial effect of omega-3 fatty acids
on depressed mood compared with placebo in patients with
diagnosis of MDD. The pooled standardized difference in means
in a random-effects model was 0.56 SD (95% CI: 0.20, 0.92). The
remaining 8 were those conducted on patients with an assessment
of depression but not rigorously diagnosed according to the DSM
criteria, and included patients with depressive symptoms despite
on-going treatment [54,69,79,97], women with borderline per-
sonality disorder [91], patients with recurrent self-harm [49],
people with mild to severe depressed mood not taking medications
[86], post-menopausal women with psychological distress and
depressive symptoms [70], and subjects with a history of at least
one major depressive episode [89], whereas two studies were
excluded due to lack of data [56,57]. Despite patients pooled in
this analysis were not homogeneous in terms of health status, all
studies clearly reported to have included subjects with no other
psychiatric or neurological illnesses such as AD, Parkinson’s
disease, as well as no history of any end-stage diseases, CVDs, or
any unstable medical conditions, thus to make them comparable
each other for our purposes. Similar results were found for this
group of patients (standardized mean difference – fixed effects-
model: 0.15 SD, 95% CI: 0.01, 0.30; random-effects model: 0.22
SD, 95% CI: 0.01, 0.43). For both MDD and non-MDD groups,
there was evidence of heterogeneity (MDD group, I2 = 71%, P,
0.001; non-MDD group, I2 = 46%, P = 0.04).
The overall analysis including both groups was conducted to
assess whether results were different considering a mood-improv-
ing effect on depressive symptoms in patients with non-organic,
metabolic, nor genetic-related neurodegenerative disease. The
pooled standardized difference in means using a fixed-effects
model was 0.27 SD (95% CI: 0.16, 0.39), and the pooled
standardized difference in means using a random-effects model
was 0.38 SD (95% CI: 0.18, 0.59). However, there was evidence of
heterogeneity (I2 = 65%, P,0.001). To test this heterogeneity, a
funnel plot was drawn and is shown in Figure 3.The funnel plot
did not show considerable evidence of asymmetry. Meta-regres-
sion of study effect size, based on study size, did not present
significant association (regression coefficient = 20.108, 95% CI:
20.224, 0.012; P = 0.066) indicating no role of the sample size in
determining the results of the analysis.
A meta-regression analysis was performed of standardized mean
depression scores on baseline depression scores to test whether the
gravity of depression at baseline may play a role in the efficacy of
omega-3 fatty supplementation. The analysis showed no relation
between baseline depression scores and efficacy for all studies
(regression coefficient = 0.019, 95% CI: 20.009, 0.047; P = 0.167)
Figure 3. Funnel plot of effect size estimates for individual trials conducted on patients with depressive disorder without
secondary comordibities (MDD group and non-MDD group, n = 19).
doi:10.1371/journal.pone.0096905.g003
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Figure 4. Forest plot examining the effect of the type of omega-3 PUFA supplementation employed on the reduction in depressive
symptoms (MDD group and non-MDD group, n = 19).
doi:10.1371/journal.pone.0096905.g004
Figure 5. Forest plot showing individual and combined effect size estimates and 95% CIs for 3 trials conducted on patients with
bipolar depression.
doi:10.1371/journal.pone.0096905.g005
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as well as for MDD patients (regression coefficient = 0.008, 95%
CI: 20.053, 0.068; P = 0.787) and non-MDD (regression coeffi-
cient = 0.019, 95% CI: 20.017, 0.054; P = 0.270) separately.
Even taking into account the comparison of studies using the same
depression scale (HDRS), no significant relation between baseline
depression scores and efficacy was found (data not shown).
Analysis conducted to explore the role of type (namely, the
administration of mainly EPA or DHA supplementation) and dose
(separately for EPA and DHA) of omega-3 supplement used
showed that the use of mainly EPA within the preparation, rather
than DHA, appeared to influence final clinical efficacy (standard-
ized mean difference – fixed effects-model: 0.46 SD, 95% CI: 0.31,
0.61; random-effects model: 0.50 SD, 95% CI: 0.27, 0.72)
(Figure 4). Despite heterogeneity fallen by 55%, it remained
significantly high (P = 0.002). When the analysis was split in mainly
EPA, pure EPA, mainly DHA, and pure DHA supplementation,
both the EPA preparations were significant (for pure EPA,
standardized mean difference – fixed effects-model: 0.40 SD, 95%
CI: 0.19, 0.61; random-effects model: 0.43 SD, 95% CI: 0.18,
0.68) and the heterogeneity fallen to 28% (P = 0.19). This result
indicates that despite the overall heterogeneity represented an
underlying true difference in effect sizes across studies, it may be
strongly affected by type of formulation of omega-3 fatty acids
used.
The meta-regression analyses exploring the role of the dose of
omega-3 fatty acids revealed that the total dose of DHA were
unrelated to efficacy (regression coefficient = 20.066, 95% CI: 2
0.471, 0.603; P = 0.801), whereas the dose of EPA formulation
resulted related to efficacy both for all MDD plus non-MDD
patients (regression coefficient = 0.477, 95% CI: 0.084, 0.869;
P = 0.02). However, when the analyses was repeated separately for
each group, the association remained significant only for MDD
patients (regression coefficient = 0.746, 95% CI: 0.100, 1.392;
P = 0.028) whereas lost significance for non-MDD patients
(regression coefficient = 0.215, 95% CI: 20.288, 0.718;
P = 0.359).
No relation between study size (regression coefficient = 2
0.109, 95% CI: 20.231, 0.012; P = 0.075, baseline depression
severity (regression coefficient = 0.026, 95% CI: 20.007, 0.060;
P = 0.116), trial duration (regression coefficient = 20.058, 95%
CI: 20.153, 0.038; P = 0.223), age of patients (regression
coefficient = 0.013, 95% CI: 20.10, 0.036; P = 0.879), and study
quality (regression coefficient = 20.142, 95% CI: 20.357, 0.072;
P = 0.183) and omega-3 PUFA efficacy was found, despite study
quality almost reached significance when considered only for
RCTs conducted on patients with MDD (regression coefficient =
20.403, 95% CI: 20.857, 0.052; P = 0.077). On the contrary,
fixed- and random-effect models of RCTs grouped by use of
omega-3 PUFA as mono- or adjuvant therapy revealed a
significant effect when they were used in combination with
standard antidepressant therapy (standardized mean difference –
fixed effects-model: 0.26 SD, 95% CI: 0.09, 0.44; random-effects
model: 0.39 SD, 95% CI: 0.06, 0.71).
Bipolar Disorder
In our systematic review we collected 7 trials conducted
on patients with bipolar disorder (both type I and II)
[58,59,61,63,65,75,80] (Table 1). The only three studies pooled
for the analysis included one study [65] that accounted for more
than 70% of the weight of the analysis, that together with others
[75,80] resulted in a significant effect of omega-3 fatty acids in
ameliorating depressive symptoms in adults with bipolar disorder
(standardized mean difference – fixed effects-model: 0.73 SD, 95%
CI: 0.39, 1.07; random-effects model: 0.74 SD, 95% CI: 0.38,
1.10; I2 = 9%, P = 0.35) (Figure 5).
Depression or Bipolar Disorder in Children and
Adolescents
Among the studies conducted on depression occurring in youth,
one study [98] documented a positive effect of omega-3 fatty acids
in improving the mood of children diagnosed of MDD and one
study conducted on adolescents at high risk of psychosis [92]
reported that omega-3 fatty acids significantly reduced positive
symptoms, negative symptoms, and improved functioning com-
pared with placebo, but no significant effect was observed on
depressive symptoms.
Perinatal Depression
There were six trials aiming to explore the effects of omega-3
PUFA on perinatal depression. We distinguished between those
Figure 6. Forest plot showing individual and combined effect size estimates and 95% CIs for 3 trials conducted on pregnant
women with major depressive disorder.
doi:10.1371/journal.pone.0096905.g006
Figure 7. Forest plot showing individual and combined effect size estimates and 95% CIs for 3 trials conducted on healthy
pregnant women for prevention of post-partum depression.
doi:10.1371/journal.pone.0096905.g007
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studies conducted on pregnant women with MDD [82,93,99]
(Figure 6) and those on apparently healthy women (primary
prevention) [51,68,85] (Figure 7). However, both analyses led to
inconclusive results (MDD in pregnancy, standardized mean
difference – fixed effects-model: 0.08 SD, 95% CI: 20.29, 0.45;
random-effects model: 0.24 SD, 95% CI: 20.73, 1.21; prevention
of post-partum depression, standardized mean difference – fixed
effects-model: 0.05 SD, 95% CI: 20.24, 0.15; random-effects
model: 20.05 SD, 95% CI: 20.24, 0.15). Only one study [82]
concluded that omega-3 fatty acids might have therapeutic
benefits in depression during pregnancy. Besides the clinical
efficacy of omega-3, in regard to the safety issue, it is important to
underline that omega-3 fatty acids supplementation was well
tolerated and no adverse effects were reported on the subjects
treated and newborns in all studies.
Depression as Secondary Outcome
Among the trials conducted in patients with primary disease
other than depression, those conducted on AD or mild cognitive
impairment [50,81] (Figure 8), schizophrenia [54,90] (Figure 9),
and CVDs [87,94,100] (Figure 10) reported inconclusive results,
whereas the only study conducted on Parkinson’s disease patients
in comorbidity with MDD [47], including those treated with
antidepressants and those without, reported improvement in
depressive symptoms and indicate that the intake of omega-3
PUFA can be used as adjuvant therapy in Parkinson’s disease
patients. However, in one study conducted on schizophrenic
patients with persistent ongoing symptoms [54], the authors
reported a large placebo effect in patients on typical and new
atypical antipsychotics and no difference was observed between
active treatment and placebo, but in patients on clozapine, there
was a clinically important and statistically significant effect of 2 g/
day omega-3 PUFA treatment on the PANSS and its sub-scales.
Depressive Symptoms in Healthy Subjects
The trials conducted on healthy subjects aimed to explore
potential beneficial effects of omega-3 fatty acids as mood
improving medicaments in the general population (Figure 11).
Among the tot studies included [52,66,67,88,101,102], the overall
analysis showed a nearly null effect of this supplement on
depressive symptoms in healthy subjects (standardized mean
difference – fixed and random effects-model: 0.00 SD, 95% CI:
20.13, 0.13).
Discussion
We demonstrated that the use of omega-3 PUFA as therapeutic
agents was effective in patients with diagnosis of MDD and on
depressive patients without a diagnosis of MDD, whereas
inconclusive results were found for patients with other pathological
conditions (namely schizophrenia and AD) as well as in healthy
subjects and perinatal depression. The analysis of the studies on
bipolar disorder showed a positive effect of the omega-3 PUFA,
but the evidence is weakened due to the exclusion from the
quantitative analysis of three studies that may affect the overall
effect of the supplement. When the studies conducted on patients
with MDD or those on patients with depressive symptoms but not
rigorous evaluation by health professionals were pooled together, a
general positive effect of omega-3 PUFA was found.
As previously reported [15], the studies that mostly negatively
influenced the pooled results of the non-MDD patients included
non-homogenous individuals, since their enrolment was in settings
such as general practice surgeries, shopping malls, and university
freshman fairs [86], newspaper, radio and television advertising,
and flyers posted [70], and through a Community Mental Health
Service, general practices, and advertisements in community
newspapers [79]. Despite the idea of a widely available low cost
supplement that could assist those being treated for a current
depressive episode in a community setting is highly desirable, a
lack of rigor in patients’ selection may lead to the inclusion of
subjects with normal emotional states, eventually affecting the
results and, thus, challenging the model’s credibility. It is
noteworthy that negative results came out mostly from studies
sharing this methodology [70,79,86]. Moreover, as reported by the
authors [79,86], both experimental and control groups improved
significantly, usually indicative of a major placebo response which
is expected to exert a meaningful clinical effect in the treatment of
such ‘‘subthreshold’’ depressed subjects [103]. A recent meta-
analysis demonstrated that the relative efficacy of the active drug
compared to placebo in clinical trials for MDD is highly
heterogeneous across studies, with a worse performance in
showing a superiority of the drug versus placebo for studies with
placebo response rates $30% [104]. Thus, the studies quality
Figure 8. Forest plot showing individual and combined effect size estimates and 95% CIs for 2 trials conducted on patients with
Alzheimer or mild cognitive impairment.
doi:10.1371/journal.pone.0096905.g008
Figure 9. Forest plot showing individual and combined effect size estimates and 95% CIs for 2 trials conducted on patients with
schizophrenia.
doi:10.1371/journal.pone.0096905.g009
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decreased when placebo response rates were not mantained below
this critical threshold that may depend on the non-homogenous
depressive ‘‘phenotypes’’ of the subjects enrolled. The non-MDD
group also included four studies conducted on patients with
depressive disorders despite ongoing antidepressant therapy
[54,69,79,97]. These results should be considered with caution,
because these studies may include those ‘‘non-responder’’ subjects
that generally fail to reach remission with the first anti-depressant
therapy and have higher relapse rates and poorer outcomes than
those who remit [105]. Studies conducted in this subgroup of
patients can explain not clearly favorable effects of omega-3 PUFA
on depressive symptoms in these studies and puzzling results.
Previous meta-analyses included all RCTs with little distinction
among population groups, leading to controversial results, such as
overall benefit [106,107] and negligible effects [27,28] of omega-3
PUFA against depressive symptoms, especially due to the high
heterogeneity of studies. The following studies improved some
methodological issues (i.e., better definition of inclusion criteria,
especially in the distinction between the definition of MDD and
other depressive disorders) and focused attention on specific
aspects of omega-3 administration (i.e., dosage, EPA:DHA ratio)
leading to the conclusion that administration of EPA, rather than
DHA, is responsible for the beneficial effects of omega-3 PUFA
intake as therapeutic agents in patients with depressive disorders
[108,109] and supplements containing EPA $60%, in dose range
from 200 to 2200 mg EPA in excess of DHA, were effective
against primary depression. On the contrary, the last meta-
analytic study [14] reported small, non-significant benefit of
omega-3 PUFA for the treatment of MDD, generally in contrast
with the aforementioned previous meta-analyses, but some
methodological issues in study selection have arisen [15,16].
Taking into account that pathophysiological processes of depres-
sive symptoms involved in MDD patients are likely to be very
different from those in patients with depression occurring in other
clinical conditions (i.e., bipolar disorder, pregnancy, primary
diseases others than depression) and in non-homogenous patients
(i.e., community sample of individuals), we used a different
approach to analyze the RCTs using omega-3 PUFA supplemen-
tation against depressive symptoms, grouping the studies by type of
diagnosis of depression and taking into account any possible health
condition that may influence the onset of the depression as well as
the response to therapy. Other meta-analyses reported that the
more severe was the depression, the more likely omega-3 PUFA
supplementation would reduce depressive symptoms. We failed to
demonstrate such a result, and we consider this finding as a
surrogate of our observation that, overall, the efficacy of omega-3
PUFA was mostly related to a specific DSM-based diagnosis of
MDD. Hence, this latter has been translated in a correlation of
efficacy to more severe symptoms whereas, according to our
results, we hypothesized that this efficacy may be more related to
the specific pathophysiological processes of the MDD rather than
to its severity. Compared with previous meta-analyses, the
differences of findings may depend on the additional number of
RCTs published since the publication of the last study
[37,40,53,60,61,66,68,69,84,89,92,94–97,100–102], the increas-
ing number of participants which vary the overall weight of
previous studies, the requirement for public registration of trials
resulting in an increase of general studies’ quality and may be
responsible for the decreased evidence of publication bias.
Since the pathophysiological mechanisms and the therapeutic
approach for bipolar disorder differ from those of MDD [22,23],
when previous analyses included and pooled findings of studies
conducted on these groups of different patients, they led to
inconclusive results. It has been hypothesized that the efficacy of
omega-3 PUFA may be different in the depressive phase rather
than the maniacal episode [110], and recent systematic analysis of
trials focused on this topic showed positive effects of omega-3
PUFA as an adjunctive treatment for depressive but not mania in
bipolar disorder patients [111,112]. Thus, we separately grouped
the studies conducted on patients with bipolar disorder and
explored efficacy of omega-3 PUFA in ameliorating the depressive
symptoms, finding a significant efficacy of the supplement in two
[65,75] out of the three trials. Despite the positive results, it is
noteworthy to underline that we had to exclude, due to missing of
data, four studies [58,59,61,63] conducted on bipolar patients
reporting poor effect of the omega-3 PUFA intervention, thus
weakening our findings. There is a need of well-designed, high
quality studies, which may clarify the potential effects of omega-3
Figure 10. Forest plot showing individual and combined effect size estimates and 95% CIs for 3 trials conducted on patients with
cardiovascular disease.
doi:10.1371/journal.pone.0096905.g010
Figure 11. Forest plot showing individual and combined effect size estimates and 95% CIs for 6 trials conducted on healthy
individuals for prevention of depressive symptoms.
doi:10.1371/journal.pone.0096905.g011
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PUFA supplement in patients with rigorously diagnosed bipolar
disorder.
Regarding the substantial inefficacy of the omega-3 PUFA in
patients with primary diseases other than depression, it may be
possible that these studies are more likely to suffer from
publication bias, since depression was often a secondary outcome.
Despite this methodological issue, the effects of the omega-3 PUFA
may have been also affected by factors particularly related to the
primary disease. Regarding the studies conducted on patients with
CVDs, the analysis included very heterogeneous populations,
namely patients with coronary heart disease [87], with diabetes
mellitus [94], and post myocardial infarction [100], that may have
been responsible for the inconclusive results. Moreover, it has been
recently reported that supplementation of EPA in diabetes mellitus
patients with comorbid MDD poorly affect biological risk factors
for adverse outcome observed in this category of patients [113].
The RCTs conducted on patients with mild cognitive impairment
or AD revealed poor efficacy of omega-3 PUFA in ameliorating
the depressive symptoms. It has been reported that molecular
mechanisms and pathways that underlie the pathogenesis of
depression (i.e., impairment in the signaling of some neurotrophins
such as Transforming-Growth-Factor-b1 and Brain-derived-neu-
rotrophic-factor) are also involved in the pathogenesis of AD
[114,115], thus the omega-3 PUFA supplementation may not be
the optimal pharmacological approach for this specific group of
patients [116–118]. The two trials (including different dosages)
conducted on schizophrenic patients with persistent ongoing
symptoms resulted in limited effects of the omega-3 PUFA on
patients’ affective states. These results may be attributable to some
psychotic symptoms (i.e., negative symptoms) that may directly
influence (i.e., improve) depression-rating scores. Moreover, these
patients were receiving different types of antipsychotics such as
first- and second-generation antipsychotics that may differently
affect (positively or negatively) the final effects of omega-3 PUFA
on depressive symptoms. Equally, we also reported that trials
focused on perinatal depression demonstrated scarce efficacy of
omega-3 on depressive symptoms. The supplemented omega-3
PUFA may have compensated the increased demand of the
developing fetus during pregnancy and neonate during lactation
rather than contributing to therapeutic efficacy by reducing
depressive symptoms [119]. Finally, depression examined as
secondary outcome could suffer by changing of the measurement
depending on the improvement (or worsening) of the underlying
primary disease.
Regarding the different efficacy of EPA compared with DHA
and EPA-DHA combinations, the analysis of RCTs grouped
according to type of omega-3 PUFA administered confirmed the
findings of previous meta-analysis and substantial stronger pooled
results of studies using EPA rather than DHA. However, as
previously reported [109], the aforementioned methodological
issues may have biased the results in favor of efficacy for EPA-
containing preparations suggesting that the reported benefits on
depressive symptoms in this group of studies may not therefore be
definitively attributed only to the EPA content of the supplemen-
tation regimen and also that further studies are needed in this field.
Whether EPA, rather than DHA, is effective in ameliorating
depression in specific groups of patients, the different effects of
these classes of omega-3 PUFA is a challenge to be explained
convincingly, since DHA is a major structural component of
neuronal membranes, and we can hypothesize that increasing its
nutritional availability would have beneficial effects on brain
function, rather than EPA, which is present at levels several
hundred-fold lower [120]. Possible explanations of the beneficial
role of EPA are the following: (i) the anti-inflammatory effects of
EPA-derived eicosanoids [121] and its oxidized derivatives [122]
(ii) its efficacy at reducing the inflammatory cytokines tumor
necrosis factor-alpha (TNF-a), IL-6, and IL-1b [123] through
inhibition of the activity of nuclear factor kappa-B (NF-kB) [124];
(iii) in vivo evidence of a more effective anti-inflammatory action of
dietary EPA compared with DHA [125]. Moreover, DHA has
been reported to be poorly incorporated in the human brain
[126], and EPA may facilitate an increase in brain DHA levels
after its conversion [127]. Finally, EPA supplementation has been
associated with N-acetyl-aspartate increase in brain, a marker for
neuronal homeostasis, suggesting its role as a neuroprotective
agent [80]. Together with the inflammation theory of depression
[8], chronic intake of omega-3 fatty acids has been reported to
play an important role in neuronal structure and function [128].
However, such hypotheses are not completely exhaustive and
further research is needed to better identify the specific molecular
mechanisms underlying clinical efficacy of omega-3 PUFA (both
EPA and DHA) in preventing or ameliorating depression.
The studies excluded from this systematic review were not
comparable in terms of methodology used, and their exclusion was
needed in order to reduce differences among RCTs and improve
data quality (i.e., reduce selection bias). On the other hand, these
trials may still be directly relevant to the topic of the present study,
and a specific discussion (e-discussion) may strengthen conclusion
retrieved from this meta-analysis. Moreover, we discussed in a
specific section of the e-discussion about the studies quality and
potential sources of heterogeneity.
The main limitation of this study was the inability to control all
the many potential sources of heterogeneity. Despite the fact that a
logical grouping of trials was performed, a non-modifiable degree
of heterogeneity, due to specific characteristics of all trials
included, still weakened the pooled analysis of these studies.
However, compared with older studies, the inclusion of the
updated RCTs strengthened the conclusions of the effects of
omega-3 PUFA intake on depressive disorders.
To sum up, trials conducted in individuals with a diagnosis of
MDD provided evidence that omega-3 PUFA supplementation
has beneficial clinical effects on depressive status. Evidence of their
efficacy was provided also for patients with bipolar disorder,
whereas no evidence was found for individuals included in the
other diagnostic groups. According to our findings, in RCTs with
omega-3 PUFA supplementation in healthy subjects and patients
with schizophrenia, AD and CVD seems to result ineffective.
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